Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2022, Vol. 27 ›› Issue (11): 1299-1306.doi: 10.12092/j.issn.1009-2501.2022.11.013

Previous Articles     Next Articles

Mechanisms of histone methylation and acetylation modifying enzymes in ovarian cancer and therapeutic advances

YUE Ling1, DU Junhong1, LIU Xiao1, LI Yulan1, XU Feixue2   

  1. 1The First Clinical Medical College of Lanzhou University, Lanzhou 730000, Gansu, China; 2Department of Obstetrics and Gynecology, the First Hospital of Lanzhou University, Key Laboratory of Gynecologic Oncology of Gansu Province, Lanzhou 730000, Gansu, China
  • Received:2022-08-09 Revised:2022-11-17 Online:2022-11-26 Published:2022-12-12

Abstract:

Ovarian cancer is the most malignant gynecologic malignancy. In recent years, histone modifying enzymes (HMEs) have been widely studied as an important part of epigenetic modifications in ovarian cancer. Histone modifying enzymes, including histone methyltransferases and demethylases, histone acetyltransferases and deacetylases, play an important role in the proliferation and migration of ovarian cancer cells by modifying histone and non-histone proteins, and can regulate the development of chemoresistance. Inhibitors of various histone modifying enzymes play good anti-tumor effects in ovarian cancer by promoting cell growth arrest and apoptosis, inhibiting tumor cell invasion, and increasing chemotherapy sensitivity, and are expected to be a new strategy for precision treatment of ovarian cancer. Therefore, this paper will review the mechanism of action and therapeutic potential of histone modifying enzymes involved in methylation and acetylation processes in ovarian cancer.

Key words: ovarian cancer, histone modifying enzymes, epigenetic therapy, precision oncology

CLC Number: